Drugs industry sits down with Government to discuss VPAS successor

Negotiations between the pharmaceutical industry, Government and NHS England around a new branded medicines pricing scheme began yesterday (May 4).

The medicines industry was represented by the Association of the British Pharmaceutical Industry (ABPI) at the initial meeting to discuss a successor to the voluntary scheme for branded medicines, pricing and access (VPAS).

A joint statement issued yesterday said that in the first meeting the aim would be to “agree to a shared negotiation aim of working toward a mutually beneficial agreement that supports better outcomes and a healthier population, a financially sustainable NHS and UK economic growth”.